Jump to content

Biomedical

These projects build on the multi-functionality allowed by 2DMs to demonstrate the advantages of combining e.g. biocompatibility, chemical stability, (bio-) sensing and actuating, and integration with flexible electronic technologies, in addition to versatile surface chemistry (for interface with biology) which allows for continuous health monitoring and built-in pharmacological interventions.

The aim is to offer new technology solutions exploiting the unique properties of 2D materials (2DM) that would reduce cost and increase the efficacy of diagnostics or therapies, or provide new diagnostics or therapies for which there is currently no solution. It would strengthen Europe’s industrial position in, early diagnostics, disease prediction and prevention, disease monitoring and reducing hospitalization time.

Projects

MUNASET

Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Latest articles

Melexis and Graphenea Accelerate Graphene Biosensor Development
2D-PL / Sensors / Biomedical

Melexis and Graphenea Accelerate Graphene Biosensor Development

Graphenea Semiconductor, a leading graphene foundry company and partner in the Graphene Flagship's 2D Pilot Line project and Melexis, a global supplier of micro-electronic semiconductor solutions, announces a strategic collaboration to accelerate the development and evaluation of Melexis’ integrated GFET-on-CMOS platform for advanced biosensing.

By Graphene Flagship / 27 November 2025
Show all news

Shortcuts